Paper40041202
Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.
Darlix A and 12 others. Neurooncol Adv, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment. Papers, record 40041202. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40041202
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19665931 | Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. | Lancet Neurol | 2009 | https://conductscience.org/library/papers/19665931 | PubMed |
| 2 | 29368212 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. | Acta Neuropathol | 2018 | https://conductscience.org/library/papers/29368212 | PubMed |
| 3 | 37272516 | Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37272516 | PubMed |
| 4 | 30258934 | InfiniumPurify: An R package for estimating and accounting for tumor purity in cancer methylation research. | Genes Dis | 2018 | https://conductscience.org/library/papers/30258934 | PubMed |
| 5 | 30753579 | Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. | Neuro Oncol | 2019 | https://conductscience.org/library/papers/30753579 | PubMed |
| 6 | 31386080 | Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. | Neurooncol Pract | 2019 | https://conductscience.org/library/papers/31386080 | PubMed |
| 7 | 27157931 | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. | Acta Neuropathol | 2016 | https://conductscience.org/library/papers/27157931 | PubMed |
| 8 | 27542245 | Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. | Oncotarget | 2016 | https://conductscience.org/library/papers/27542245 | PubMed |
| 9 | 37585632 | Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37585632 | PubMed |
| 10 | 32166314 | MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/32166314 | PubMed |
| 11 | 22810491 | MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. | Acta Neuropathol | 2012 | https://conductscience.org/library/papers/22810491 | PubMed |
| 12 | 27050206 | Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27050206 | PubMed |
| 13 | 16632515 | Adjusting batch effects in microarray expression data using empirical Bayes methods. | Biostatistics | 2007 | https://conductscience.org/library/papers/16632515 | PubMed |
| 14 | 28640707 | Response Assessment in Neuro-Oncology Clinical Trials. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28640707 | PubMed |
| 15 | 16168780 | Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. | Lancet | 2005 | https://conductscience.org/library/papers/16168780 | PubMed |
| 16 | 11146149 | Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. | Control Clin Trials | 2000 | https://conductscience.org/library/papers/11146149 | PubMed |
| 17 | 27686946 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27686946 | PubMed |
| 18 | 25008768 | Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. | Acta Neuropathol | 2014 | https://conductscience.org/library/papers/25008768 | PubMed |
| 19 | 15758010 | MGMT gene silencing and benefit from temozolomide in glioblastoma. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15758010 | PubMed |
| 20 | 39277807 | MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma. | Neuro Oncol | 2024 | https://conductscience.org/library/papers/39277807 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42313202 | MGMT promoter methylation across glioma subtypes: biological relevance, treatment response, and survival outcomes. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42313202 | PubMed |
| 41677997 | Targeting metabolic mechanisms to overcome temozolomide resistance in glioblastoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41677997 | PubMed |
| 41460180 | Distinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytomas and oligodendrogliomas. | Neuro Oncol | 2026 | https://conductscience.org/library/papers/41460180 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40041202
GET https://conductscience.org/api/papers/v1/40041202/references?page=2